Aadi bioscience to present multiple posters at the american association for cancer research (aacr) annual meeting 2023

Los angeles , april 6, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that it will present three posters at the american association for cancer research annual meeting (aacr) 2023, taking place april 14-19, 2023, in orlando, fl.  the details of the poster presentations are below: title: "phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in tsc1 or tsc2 (precision i) " date and time: monday, april 17, 2023, 9:00 am - 12:30 pm session title: phase ii and phase iii clinical trials in progress  presentation number: ct057 title: "synergistic anti-tumor activity of nab-sirolimus in combination with kras inhibitors (krasis) sotorasib and adagrasib in kras g12c nsclc and bladder cancer xenografts" date and time: tuesday, april 18, 2023, 1:30 - 5:00 pm session category: clinical research excluding trials session title: poster combination therapies for cancer presentation number: 5484 title: " biomarker analysis from ampect correlating response to nab-sirolimus with tsc1 and tsc2 inactivating alterations " date and time: wednesday, april 19, 2023, 9:00 am - 12:30 pm session category: clinical research excluding trials session title: late-breaking research: clinical research 3 presentation number: lb288 full session and meeting details are available through the aacr annual meeting planner: aacr annual meeting 2023 | meetings | aacr.
AADI Ratings Summary
AADI Quant Ranking